SCIENTIFIC BACKGROUND

SPRED1

Category:

Legius syndrome, historically known as Neurofibromatosis type 1-like syndrome (NFLS), is characterized by multiple café-au-lait spots with or without additional freckle-like spots in the axilla or groin. In addition, macrocephaly, learning difficulties, and developmental delay may be present. Thus, the diagnostic criteria of the NIH Consensus Development Conference Statement are overlapping with the diagnosis of neurofibromatosis type 1, and no clinical differentiation from NF1 is possible. A distinctive difference from NF1 in patients with Legius syndrome is the absence of other clinical NIH criteria such as Lisch nodules of the iris, neurofibromas, optic gliomas, typical bone changes, and possibly nodule-like changes of the choroid. In contrast, Legius syndrome involves subcutaneous lipomas occurring in adulthood.

 

Legius syndrome can be confirmed by detection of a pathogenic variant in the SPRED1 gene. SPRED1 (Sprouty-Related EVH1 Domain Containing 1) is a member of the so-called Sprouty (SPRY) family of proteins that function as negative regulators within mitogen-activated protein kinase (MAPK) signal transduction. Approximately 90% of variants are small nucleotide changes in the SPRED1 gene, with larger genomic deletions or duplications present in 10% of patients. Most pathogenic variants result in premature translational stop in protein biosynthesis and loss of protein function upon inhibition of Raf1 kinase activation. In classical neurofibromatosis type 1, pathogenic variants in the NF1 gene can be detected in up to 95% patients if more than two clinical NIH criteria are met. In contrast, the detection rate of pathogenic variants in the SPRED1 gene is about 2% in sporadic patients with NF1-like phenotype or Legius syndrome, and up to 19% in patients with a positive family history including the presence of café-au-lait spots and freckling without other clinical criteria for NF1.

 

References

Tucci et al. 2017, J Hum Genet 62:1001 / Stevenson et al, In: Adam, Ardinger, Pagon, et al, editors. GeneReviews® (Updated 2015 Jan 15) / Pasmant et al. 2015, Eur J Hum Genet 23:596 / Brems et al. 2012, Hum Mutat 33:1538 / Spencer et al. 2011, Am J Med Genet A 155:1352 / Muram-Zborovski et al. 2010, J Child Neurol 25:1203 / Messiaen et al. 2009, JAMA 18:2111 / Brems et al. 2007, Nat Genet 39:1120

GENES

SPRED1

ASSOCIATED TESTS

How to order

LATEST ARTICLES

Traditional DNA tests may overlook 10% of classic in Familial Adenomatous Polyposis (FAP) cases. By integrating RNA sequencing, researchers unveiled ...

Read more

Overview In January 2024, the American Society of Clinical Oncology (ASCO) and the Society of Surgical Oncology (SSO) published new recommendation...

Read more

Endometriosis is a chronic gynecological condition that affects 1 in 10 women of reproductive age worldwide [1]. It can manifest with the first menst...

Read more

Rare Disease Day is a global awareness day held annually to raise awareness of all rare diseases. It was first celebrated in 2008, on the rarest day ...

Read more

Cancer is a group of genetic diseases that can develop almost anywhere in the body. Many people in the world are affected by cancer every year. Follo...

Read more

Aiming to evaluate the role of chromosomal aneuploidy in pregnancy loss, a 2023 study 35 years in the making evaluated the genomic landscape of first...

Read more

Cancer is a complex genetic disease that affects millions of people in the world. It is one of the leading causes of death worldwide, with about ten ...

Read more

Researchers created a detailed map of the placenta during labor. By studying how maternal and fetal cells communicate, they discovered signals in the...

Read more

A recent paper published in Nature Medicine (1) aimed to identify genes and genomic biomarkers which can better predict outcomes and personalized the...

Read more

In honor of the international day of women and girls in science, we interviewed one of our very own, Dr. Evelina Papaioannou. Dr. Evelina Pa...

Read more